We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Asthma Clinical Research Network (ACRN) Trial - Best Adjustment Strategy for Asthma in Long Term (BASALT) (BASALT)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00495157
First Posted: July 2, 2007
Last Update Posted: April 11, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
National Heart, Lung, and Blood Institute (NHLBI)
Information provided by (Responsible Party):
Vernon M. Chinchilli, PhD, Milton S. Hershey Medical Center
Results First Submitted: April 30, 2012  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Condition: Asthma
Interventions: Behavioral: Symptom-based adjustment
Behavioral: Biomarker-based adjustment
Behavioral: Guideline-based adjustment

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Symptom-based Adjustment Symptom-based adjustment of beclomethasone dipropionate administered via a hydrofluoroalkane (HFA) inhaler (QVAR® 40 mcg or QVAR® 80 mcg)
Biomarker-based Adjustment Biomarker-based adjustment of beclomethasone dipropionate administered via a hydrofluoroalkane (HFA) inhaler (QVAR® 40 mcg or QVAR® 80 mcg)
Guideline-based Adjustment Guideline-based adjustment of beclomethasone dipropionate administered via a hydrofluoroalkane (HFA) inhaler (QVAR® 40 mcg or QVAR® 80 mcg)

Participant Flow:   Overall Study
    Symptom-based Adjustment   Biomarker-based Adjustment   Guideline-based Adjustment
STARTED   113   115   114 
COMPLETED   97   92   101 
NOT COMPLETED   16   23   13 



  Baseline Characteristics


  Outcome Measures

1.  Primary:   Time to Treatment Failure (Measured in Days)   [ Time Frame: Measured during the 36-week treatment period ]

2.  Secondary:   Number of Episodes of Treatment Failure   [ Time Frame: Measured during the 36-week treatment period ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.  

3.  Secondary:   Time to First Asthma Exacerbation   [ Time Frame: Measured during the 36-week treatment period ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.  

4.  Secondary:   Number of Asthma Exacerbations   [ Time Frame: Measured during the 36-week treatment period ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.  

5.  Secondary:   Tests of Airway Caliber and Responsiveness (Forced Expiratory Volume in One Second (FEV1) Pre- and Post-bronchodilator Inhalation), Methacholine Provocative Concentration at 20% (PC20)   [ Time Frame: Measured during the 36-week treatment period ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.  

6.  Secondary:   Tests of Airway Inflammation (Exhaled Breath Condensate (EBC), Fractional Exhaled Nitric Oxide (FeNO), Sputum Eosinophils)   [ Time Frame: Measured during the 36-week treatment period ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.  

7.  Secondary:   Quality-of-life (AQLQ), Asthma Control Questionnaire (ACQ), and Number of Visit Days That ACQ is Less Than 1.25   [ Time Frame: Measured during the 36-week treatment period ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.  

8.  Secondary:   Total Amount of Oral Prednisone Required and Total Amount of Inhaled Steroids   [ Time Frame: Measured during the 36-week treatment period ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.  

9.  Secondary:   Adverse Events   [ Time Frame: Measured during the 36-week treatment period ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.  


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information